Emerald Mutual Fund Advisers Trust Arvinas, Inc. Transaction History

Emerald Mutual Fund Advisers Trust

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$26.15 - $37.26 $2.83 Million - $4.03 Million	-108,233 Reduced 44.64%	134,249 $3.67 Million
Q4 2022 Feb 03, 2023	BUY	$32.47 - $57.24 $1.32 Million - $2.32 Million	40,553 Added 20.08%	242,482 $8.3 Million
Q3 2022 Oct 25, 2022	SELL	$41.87 - $57.99 $1.11 Million - $1.54 Million	-26,562 Reduced 11.62%	201,929 $8.98 Million
Q2 2022 Jul 29, 2022	SELL	$36.01 - $74.24 $94,706 - $195,251	-2,630 Reduced 1.14%	228,491 $9.62 Million
Q1 2022 Apr 29, 2022	SELL	$60.27 - $81.57 $4.31 Million - $5.83 Million	-71,448 Reduced 23.61%	231,121 $15.6 Million
Q4 2021 Feb 02, 2022	BUY	$65.85 - $96.21 $542,604 - $792,770	8,240 Added 2.8%	302,569 $24.9 Million
Q1 2021 Apr 29, 2021	BUY	$58.19 - $91.37 $2.99 Million - $4.69 Million	51,351 Added 21.13%	294,329 $19.5 Million
Q4 2020 Jan 29, 2021	BUY	$20.19 - $84.93 $4.91 Million - $20.6 Million	242,978 New	242,978 $20.6 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.